Chimerix, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Michael T. Andriole
- Full Time Employees
- 79
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 2505 Meridian Parkway Durham NC United States of America 27713
- IPO Date
- Apr 11, 2013
- CIK
- 0001117480
- Website
- chimerix.com
- Similar Companies
- Business
- Chimerix, Inc. (NASDAQ: CMRX) is a biopharmaceutical company that develops medicines to improve and extend the lives of patients facing deadly diseases, with a primary focus on oncology therapies for high-grade gliomas and other solid tumors as well as antiviral treatments; its lead product candidate is dordaviprone (ONC201), an imipridone in phase 3 clinical development for recurrent H3 K27M-mutant diffuse glioma and phase 2 investigator-initiated trials for additional oncology indications, while ONC206, a second-generation imipridone ClpP agonist and DRD2 antagonist, advances in phase 1 trials for central nervous system and solid tumors; it also markets TEMBEXA (brincidofovir) for adult and pediatric patients with smallpox disease. Founded in 2000 and headquartered in Durham, North Carolina, the company originally pioneered lipid conjugate technology for broad-spectrum antivirals before shifting emphasis to oncology, conducting research and development, clinical trials, regulatory affairs, manufacturing, and commercialization primarily in the United States with a niche in unmet needs for transplant recipients, immunocompromised patients, and rare cancers. In April 2025, Jazz Pharmaceuticals plc completed its $935 million acquisition of Chimerix, making it a wholly owned subsidiary and integrating dordaviprone's New Drug Application under FDA Priority Review with a PDUFA target date of August 18, 2025, to bolster Jazz's late-stage oncology pipeline and enable potential commercial launch in the second half of 2025.
Jazz Pharmaceuticals Completes Acquisition of Chimerix
Biotech Stocks Q1 2025 Recap: Winners And Underperformers
Chimerix Reports Fourth Quarter and Year End 2024 Financial Results
CHIMERIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Chimerix, Inc. - CMRX
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CMRX Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Chimerix, Inc. is Fair to Shareholders
The Zacks Analyst Blog Jazz Pharmaceuticals, Chimerix, Moderna, GSK and Regeneron Pharmaceuticals
Biotech Stocks Roundup: CMRX Up on JAZZ Bid, MRNA Up on Updates & More
Jazz Offers to Buy Chimerix for $935M to Boost Oncology Portfolio
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Chimerix, Inc. - CMRX
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CMRX and GLYC on Behalf of Shareholders
Jazz Pharma To Buy Chimerix For $935 Million, Strengthening Rare Cancer Pipeline
Jazz Pharmaceuticals to buy Chimerix for $935 million
Jazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio
Jazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio
Chimerix: Potential 'First' In Targeting Recurrent High-Grade Glioma Patients
Here's Why Momentum in Chimerix (CMRX) Should Keep going
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CMRX Stock Skyrockets in 3 Months: Here's What You Should Know
Chimerix to Present at JonesTrading Virtual Precision Medicine Symposium